Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03633721 · ClinicalTrials.gov registry record · Phase 2
Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03633721: Completed Phase 2 study, sponsored by Albert Einstein College of Medicine.
NCT03633721 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03633721, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to try to understand and explain why HIV-infected and uninfected women who use cannabis (marijuana) currently, or have used cannabis in the past, have higher risk of having experienced a fall in our earlier analyses in WIHS. This study will compare what happens when women are given cannabis compared with placebo, on measures of mobility, including walking speed under walking conditions that vary in terms of difficulty; for example normal walking and walking while reciting alternate letters of the alphabet, as well as measures of balance and cognition (for example attention, memory).
Primary Outcome
Mobility Gait Speed will be tested using the timed gait speed test. Gait speed is measured and reported under normal walking and attention demanding measures. Change in mobility as a function of timed gait speed from before cannabis, or placebo use, to after cannabis, or placebo, use at the 15 minute and 60 minute timepoints will be assessed. The baseline measurement, the mean of the two timepoint measurements, changes from the baselines, and change from the baseline to mean of 15 \& 60 minutes
Interventions
- OTHER Placebo
- DRUG Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
What the finished NCT03633721 record still lists
NCT03633721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03633721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03633721 about?
NCT03633721 is a clinical study titled "Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women". The purpose of this study is to try to understand and explain why HIV-infected and uninfected women who use cannabis (marijuana) currently, or have used cannabis in the past, have higher risk of having experienced a fall in our earlier analyses in WIHS. This study will compare what happens when wome...
What is the current status of trial NCT03633721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-10-23. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03633721?
The interventions under investigation include: Placebo (OTHER), Cannabis (DRUG).
Who is sponsoring clinical trial NCT03633721?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03633721's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI